AML is swarming with challenges

Acute myeloid leukemia (AML) is a complex disease that evolves rapidly, with a distinct pattern of molecular abnormalities.[1] While alterations to FLT3 are at the center of this attack, other important kinases and proteins are also involved.[1,2]

Novartis Oncology is committed to advancing research into these diverse pathways to help find new options for patients with AML.

References: 1. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. *Lancet.* 2013;381:484-495. **2.** Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *N Engl J Med*. 2012;366:1079-1089.

NOVARTIS
ONCOLOGY